Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma
Status:
Recruiting
Trial end date:
2026-01-13
Target enrollment:
Participant gender:
Summary
This is a prospective single arm, multi-center, phase II clinical trial to observe the
efficacy and safety of Rituximab, Lenalidomide combined with high-dose Methotrexate and
Temozolomide (RL-MT) in the first-line treatment for patients with primary central nervous
system lymphoma.